Brickell Biotech, Inc. (NASDAQ:BBI – Get Rating) fell 5.8% during trading on Tuesday . The company traded as low as $1.85 and last traded at $1.94. 68,775 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 206,730 shares. The stock had previously closed at $2.06.
Brickell Biotech Price Performance
The firm has a 50-day moving average of $2.93 and a 200 day moving average of $6.93. The company has a market capitalization of $5.58 million, a PE ratio of -0.14 and a beta of 0.02.
Brickell Biotech (NASDAQ:BBI – Get Rating) last released its earnings results on Thursday, August 11th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($1.48) by $1.47. Brickell Biotech had a negative net margin of 643.48% and a negative return on equity of 156.10%. During the same period in the prior year, the firm earned ($7.21) EPS. Equities analysts expect that Brickell Biotech, Inc. will post -7.66 EPS for the current year.
Hedge Funds Weigh In On Brickell Biotech
Brickell Biotech Company Profile
Brickell Biotech, Inc, a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors.
- Get a free copy of the StockNews.com research report on Brickell Biotech (BBI)
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
Receive News & Ratings for Brickell Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brickell Biotech and related companies with MarketBeat.com's FREE daily email newsletter.